Related Experiment Videos
Hepatitis C virus detection is facilitated by the combined use of c100 protein and GOR epitope
J Hayashi1, K Nakashima, M Hirata
1Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
Insights
A combined assay for antibodies to Hepatitis C Virus (HCV) c100 protein and GOR epitope improves detection rates. This dual testing reveals higher HCV prevalence in non-A, non-B liver disease patients compared to single antibody tests.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection diagnosis relies on antibody detection.
- The anti-c100 assay alone shows limited sensitivity for HCV detection.
- The role of anti-GOR antibodies in HCV diagnosis requires further investigation.
Purpose of the Study:
- To evaluate the diagnostic accuracy of combined anti-c100 and anti-GOR assays for HCV detection.
- To determine the prevalence of HCV infection in various patient groups in Japan.
- To assess the correlation between antibody presence and liver disease severity.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to detect anti-c100 and anti-GOR antibodies.
- Study population included chronic liver disease patients and volunteer blood donors.
- HCV infection prevalence was calculated based on antibody detection.
Main Results:
- Combined anti-c100 and anti-GOR assays detected a higher prevalence of HCV in non-A, non-B liver disease patients (89.5%) compared to anti-c100 alone (82.5%).
- HCV prevalence varied across different groups: 3.9% in blood donors, 12.7% in those with abnormal liver function, and 7.4% in HBsAg-positive liver disease patients.
- The concurrence of both antibodies increased with liver disease severity.
Conclusions:
- Combination assays for anti-c100 and anti-GOR provide a more accurate assessment of HCV infection prevalence.
- Anti-GOR antibodies play a significant role in liver disease among anti-HCV-positive individuals.
- Enhanced diagnostic strategies are crucial for understanding HCV epidemiology.
Abstract:
Assay for the antibody to the c100 protein (anti-c100) lacks sensitivity in terms of detection of hepatitis C virus (HCV) in all samples. The author used anti-c100 and antibody to the GOR epitope (anti-GOR) by the enzyme-linked immunosorbent assay to examine 524 patients with chronic liver disease and 682 volunteer blood donors in Fukuoka, Japan. The prevalence of HCV infection, as revealed by the presence of anti-c100 and/or anti-GOR, was 3.9% in 540 volunteer blood donors, 12.7% in 142 volunteers with abnormal liver function, 7.4% in 135 patients with HBsAg-positive liver disease and 89.5% in 389 patients with non-A, non-B (NANB) liver disease. These results show a higher prevalence than demonstrated only by the anti-c100 in NANB liver disease patients (82.5%, P < 0.01). The concurrence of anti-c100 and anti-GOR in subjects with HCV infection was 23.8% in 21 volunteer blood donors, 44.4% in 18 volunteers with abnormal liver function and 61.2% in 348 NANB liver disease patients. The concurrence seems to increase with deterioration of liver function. We concluded that combination assay for anti-c100 and anti-GOR demonstrated a more accurate prevalence of HCV infection than single assay for anti-c100 among NANB liver disease patients, and that the presence of anti-GOR plays a role in liver disease in anti-HCV-positive subjects.